INCR
InterCure Ltd.
There isn't enough reported data to score INCR yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
INCR Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Healthy |
INCR's balance sheet is currently healthy, but its profitability is under pressure. There isn't enough data to rate its revenue and cash flow.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
INCR PE Valuation
INCR has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
INCR Forward outlook
There aren't enough analyst estimates for INCR to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
INCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$2.32 | -$0.18 |
| Q4 2023 | -$2.14 | -238% |
| Q4 2022 | $1.55 | +812% |
| Q4 2021 | $0.17 | +$2.61 |
| Q4 2020 | -$2.44 | -$2.25 |
| Q3 2020 | -$3.93 | -1059% |
| Q2 2020 | -$5.04 | -567% |
| Q1 2020 | -$5.75 | -459% |
LLY has the stronger earnings trend. Trailing diluted EPS is down 195% for INCR versus LLY up 51%.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
INCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2024 | $75M | -33% |
| Q4 2023 | $111.7M | -8.5% |
| Q4 2022 | $122.1M | +77% |
| Q4 2021 | $69M | +711% |
| Q4 2020 | $8.5M | +1382% |
| Q3 2020 | $7.1M | +766% |
| Q2 2020 | $3.5M | +303% |
| Q1 2020 | $1.3M | +147% |
INCR has the stronger quarterly revenue trend. Revenue is up 782% for INCR versus up 39% for LLY.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2024 | -28% | -56 points |
| Q4 2023 | -12% | -22 points |
| Q4 2022 | 13% | +21 points |
| Q4 2021 | 13% | +1125 points |
| Q4 2020 | 28% | +765 points |
| Q3 2020 | 11% | +566 points |
| Q2 2020 | -7.6% | +363 points |
| Q1 2020 | -1113% | -3300 points |
INCR's operating margin was −28% last quarter, down 56 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY's revenue has grown year over year for 14 quarters in a row: $24.4B last quarter, up 39% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
INCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$22.4M | -$4.7M |
| Q4 2023 | -$17.7M | -278% |
| Q4 2022 | $9.9M | +187% |
| Q4 2021 | $3.5M | +136% |
| Q4 2020 | $1.5M | -84% |
| Q3 2020 | $525.2K | +$5.5M |
| Q2 2020 | -$2.9M | +$1.4M |
| Q1 2020 | -$3.1M | -$2.3M |
LLY has the stronger cash trend. Its trailing FCF is up 259% versus its history, compared with INCR at down 3,189%.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
INCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +59.3K shares |
| 1 year | +81% | +4.1M shares |
| 3 years | +138% | +5.3M shares |
| 5 years | +256% | +6.6M shares |
| Available history | +344% | +7.1M shares |
INCR has 9M diluted shares, up 81% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
| Q1 2019 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over INCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
INCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -0.1x | Net Cash |
| Q4 2021 | -3.2x | Net Cash |
| Q4 2020 | -3.7x | Net Cash |
| Q3 2019 | -0.4x | Net Cash |
| Q2 2019 | -2.1x | Net Cash |
| Q1 2019 | 0.3x | Very low |
| Q4 2016 | -0.4x | Net Cash |
INCR has more cash than debt.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
INCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.2 | Neutral |
| Stochastic | 13.5 | Oversold |
INCR's weekly RSI is 42 (neutral) and its Stochastic is 14 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
INCR PE vs Healthcare Sector
| Metric | INCR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
INCR has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
INCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.54 | 12% below |
| 20 week MA | $4.83 | 18% below |
| 50 week MA | $4.77 | 17% below |
| 100 week MA | $6.21 | 36% below |
| 200 week MA | $8.06 | 51% below |
INCR is in a downtrend: it's below all five of its weekly moving averages, and 51% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over INCR on trend strength, trading above more of its moving averages.
INCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.45 | $6.00 | +10% |
| 2021 | $6.00 | $36.0 | +500% |
| 2022 | $36.0 | $19.2 | -47% |
| 2023 | $19.2 | $6.45 | -66% |
| 2024 | $6.45 | $8.15 | +26% |
| 2025 | $8.15 | $5.65 | -31% |
| 2026 YTD | $5.65 | $3.98 | -30% |
INCR's yearly returns have swung widely, from +500% in 2021 to −66% in 2023. It's down 30% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over INCR on returns for 2026, with the stronger performance.